ibmc01 ibmc02 ibmc03 ibmc04 ibmc05 ibmc06 ibmc07 ibmc08 ibmc09 ibmc10 ibmc11 ibmc12
jQuery Image Slider by v2.0
web del Instituto de Biología Molecular y Celular
Dr. Antonio Vicente Ferrer Montiel

Unit: Molecular and Cellular Design
Subunit: Molecular Recognizement and Protein Engineering
Group: Sensory Neurobiology
Category: Investigator
Phone: + 34 966 65 87 27
Degree: Chemistry
Ph.D program: 1.-Molecular Neurosciences, Institute of Neurosciences, Universidad de Alicante,1989 (Director: Prof. José A. Ferragut)
2.-Awarded the Prize to the Best Thesis, Universidad de Alicante, 1990.
Postdoctoral positions: 1.- Department of Physics, University of California San Diego, 1990-1993.
2.- Department of Biology, Universitsy of California San Diego, 1993-1997.
Previous positions:
1. Fellowship from the Ministry of Health, Universidad de Alicante, Spain, 1986-1989.
2. Postdoctoral fellowship from the Ministry of Education, University of California San Diego, 1990-1992.
3.-Postdoctoral fellowship from NATO, University of California San Diego, 1993.
4. Postgraduate Researcher, University of California San Diego, 1994-1996.
5.-Assistant Project Scientist Step II; Dept. Biology, UCSD, USA. 1996.
6.-Assistant Project Scientist Step III. Dept. Biology, UCSD, USA. 1997.
7.-Assistant Professor of Biochemistry and Molecular Biology (Tenure-Track). University Miguel Hernández (UMH), Spain. 1999.
8.-Associate Professor (Tenure), UMH, Spain. 1999-2007.
9.-Full Professor, UMH, Spain. 2007-present.
10.-Director, Institute of Molecular and Cellular Biology, 2012-present.
Current Position: Professor of Biochemistry and Molecular Biology, 2007-present.
Research Fields:
-Sensory neurobiology with a focus on molecular and cellular mechanisms of pain transduction.
-Discovery and development of anti-nociceptive drugs.
-Structure-function studies on thermo-sensory ion channels.
Representative Publications:

  • Devesa I, Wolf C, Mathivanan S, Ferrandiz-Huertas C, Lujan R, and Ferrer-Montiel A. alpha-CGRP is essential for pro-algesic sensitization of TRPV1 in peptidergic C-type nociceptors. Proc. Natl. Acad. Sci. USA. 111. 18345-18350. 2014
  • Taberner F, López-Cordoba A, Fernandez-Ballester G, Korchev and Ferrer-Montiel A. The S6-TRPbox linker domain in TRPM8 plays a central role in allosteric channel activation. J. Biol. Chem. 289, 28579-28594. 2014
  • Bonache MA, Balsera B, Martin-Somer A, López-Méndez B, Millet O, Brancaccio D, Gómez-Monterrey I, Carotenuto A, Pavone LM, Vidal M, de la Torre, R, Fernández-Carvajal A, Ferrer-Montiel A, García-López MT, Martí-Martínez M, Pérez de Vega MJ and González-Muñiz R. De novo design, synthesis, structure and validation of a library of helical peptides for modulation of protein-protein interactions. ACS. Sci. Chem. 16, 250-258. 2014
  • Gregorio-Teruel L, Valente P, González-Ros JM, Fernandez-Ballester G and Ferrer-Montiel A. Mutation of I696 and W697 in the trp box of vanilloid receptor subtype modulate allosteric channel activation. J. Gen. Physiol. 143,361-375. 2014
  • Devesa I and Ferrer-Montiel A. Neurotrophins, endocannabinoids and thermoTRPs: a threesome in pain signaling. Eur. J. Neurosci. 39, 353-362. 2014
Patents and Available Technologies:
  1. Blanes C, Llobregat M, Gil A, Fernández-Ballester G, Planells Cases R, Viniegra S, Gutierrez LM, Carbonell T, Pérez-Payá E, Ferrer-Montiel. A. Neuronal exocytosis inhibiting peptide and cosmetic composition and pharmaceutical composition containing the peptide. ES2160482 B1 (granted on 18/04/2002); EP1180524 B1 (granted on 30/08/2006); CA2370289 A1; US7015192 B1 (granted on 21/03/2006); US77473679 B1 (granted on 21/03/2006).
  2. Planells Cases, R., García-Martínez C, González-Ros JM, Merino J, Belmonte C, Gallar J, Pérez- Payá E, Sánchez-Baeza F, Humet M, Messeguer A, Ferrer-Montiel A. N-alkylglycine trimeres capable of blocking the response to chemical substances, thermal stimuli or mediators of neuronal receptor inflammation and compositions containing said trimeres. ES2169691 B1 (granted on 16/03/2004); WO02/30956; EP1338605 A1; US2004/33958; AU9388201; BR200114802 A; CA2425520 A1; JP2004/511491; MX PA/a/03003158
  3. Felipo V, Montoliu C, Planells Cases R, Merino J, Pérez-Payá E, Sánchez-Baeza F, Humet M, Messeguer A, Ferrer-Montiel, A. N-alkylglycine trimeres capable of protecting neurons against excitotoxic aggressions and compositions containing such trimeres. ES2169690 B1 (granted on 16/03/2004); ES2267816 T3 (granted on 16/03/2007); WO02/28885; EP1338604 B1 (granted on 12/07/2006); US6992064 B1 (granted on 31/01/2006); AU2001291906 A; BRPI0114660 A; CA2427072 A1; JP2002-532467; KR 849739 (granted on 01/08/2008); MX244057 B (granted on 09/03/2007)
  4. Fernández-Carvajal A, García-Martínez C, Belmonte C, Van Den Nest W, Carreño C., Ferrer-Montiel A. Compounds which can block the responses to chemical substances or thermal stimuli or mediators of inflammation of nociceptors, production method thereof and compositions containing same. ES2195787 B1 (granted on 01/06/2005); WO03/097670; EP1506970 A1; US7183430 B2 (granted on 27/02/2003); AU2003/231331; CA2486342 A1; JP2006/502975 ; MX PA/a/04011502
  5. Ferrer-Montiel A, Cebrián J, Puig A. Dermopharmaceutical or cosmetic composition comprising enkephaline-derived peptides for reducing and/or eliminating facial wrinkles. ES2259928 B1 (granted on 06/09/2007); WO2006/106164; EP1892247 A1; US11/910719; AU2006231273; BR 0609745-6; CA2608165 A1; JP2008-504786; MX PA/a/2007012504.
Company agreements:
  • BCN Peptides
  • DiverDrugs